Hope for Depression Research Foundation Advances Precision Psychiatry with New Findings on Potential Treatment Targets
PR Newswire
NEW YORK, Nov. 19, 2026
Studies highlight advances in depression biology, stress resilience, and innovative drug discovery at Neuroscience 2026
- Human brain research reveals changes associated with depression, including disrupted development of new neurons.
- Stress resilience findings uncover biological mechanisms that may help explain differences in vulnerability to depression.
- Drug discovery studies identify promising ways to target brain cells and proteins relevant to depression.
NEW YORK, Nov. 19, 2026 /PRNewswire/ -- Hope for Depression Research Foundation (HDRF) today highlighted findings from three studies presented by researchers from its Depression Task Force (DTF) at Neuroscience 2026, the Society for Neuroscience's annual meeting in Washington, D.C.
The research advances HDRF's Precision Psychiatry Initiative, announced last week, which aims to move beyond symptom-based diagnosis and trial-and-error treatment, toward understanding the biological differences that could lead to more effective, personalized treatments.
"Depression is not one illness with one cause," said Audrey Gruss, Founder and Chair of HDRF. "Understanding the biological differences between patients is essential to developing better treatments. Now our scientists are turning years of research into promising new directions for treatment discovery."
New avenues for antidepressant development
Conor Liston, MD, PhD, of Weill Cornell Medicine presented findings showing that a combination of experimental drug candidates targeting serotonin, glutamate and opioid receptor systems rapidly reduced activity in brain cells implicated in depression. The findings suggest that targeting multiple pathways simultaneously could offer a new approach to developing fast-acting antidepressants.
Eric Nestler, MD, PhD, Dean of the Icahn School of Medicine at Mount Sinai presented a late-breaking study demonstrating that experimental compounds can block the activity of ΔFOSB (delta-FOSB), a protein regulating gene activity in the brain and associated with stress susceptibility. The protein has been difficult to target with drugs. One compound reduced its binding to DNA by 94% in a mouse-brain experiment, providing early proof of concept for a new approach to drug discovery.
Changes in human brain in depression
René Hen, PhD, of Columbia University presented findings from an analysis of approximately 500,000 cell nuclei from human hippocampus, a brain region involved in memory and emotion. Comparing tissue from individuals with and without depression, researchers identified disruptions in the development of new neurons, alongside changes in stress and inflammatory pathways. The findings detail the underlying biology of depression and point to potential targets for future treatments.
Advancing Precision Psychiatry
Together, these findings illustrate HDRF's approach: understanding depression biology, identifying promising treatment targets, and advancing the target toward human studies.
About the Hope for Depression Research Foundation
Founded in 2006 by Audrey Gruss in memory of her mother Hope, HDRF funds neuroscience research into the origins, diagnosis, treatment, and prevention of depression and related mood disorders.
Its Depression Task Force brings together nine leading neuroscientists from seven institutions: Columbia University, Duke University, the Icahn School of Medicine at Mount Sinai, McGill University, the Max Planck Institute of Psychiatry, the University of Michigan, and Weill Cornell Medicine. The scientists work collaboratively on a shared research roadmap, sharing data across laboratories to accelerate discovery.
For more information, visit www.hopefordepression.org.
Research Presented at Neuroscience 2026
The following abstracts can be found in the Neuroscience 2026 scientific program these identifiers:
- LBP014.25 — Efficient in vivo pharmacological inhibition of ΔFOSB, an AP1 transcription factor, in brain — Eric Nestler and colleagues, November 15, 2026.
- LBP011.17 — Multi-drug inhibition of somatostatin-expressing interneurons of the medial prefrontal cortex — Conor Liston and colleagues, November 15, 2026.
- PSTR337.05 — Molecular landscapes of human hippocampus in major depressive disorders — René Hen and colleagues, November 18, 2026.
Media Contact
Zina McGowan-Thomas
zthomas@lavoiegroup.com
Ludivine Delattre
ldelattre@lavoiegroup.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-for-depression-research-foundation-advances-precision-psychiatry-with-new-findings-on-potential-treatment-targets-302945608.html
SOURCE Hope for Depression Research Foundation
